GE HealthCare Completes Spin-Off and Begins Trading on Nasdaq
January 04 2023 - 06:20AM
Business Wire
- A leader in precision care, focused on creating a world where
healthcare has no limits
- Attractive financial profile supported by commitment to
accelerating growth, margin expansion, and free cash flow
generation through organic investment, business optimization, and
disciplined capital allocation
- Trading on Nasdaq exchange under “GEHC” ticker symbol
GE HealthCare (Nasdaq: GEHC) announced today that its previously
announced spin-off from GE (NYSE: GE) is complete and GE HealthCare
will begin trading as an independent company on the Nasdaq exchange
under the ticker symbol “GEHC” effective at the market opening
today. GE HealthCare will be the first company in the state of
Wisconsin to remotely ring Nasdaq’s opening bell. Its leadership
team will be joined by employees in person and virtually from
around the world at the Company’s manufacturing facility in
Waukesha, Wis.
“Today is an incredibly exciting day for GE HealthCare as we
become an independent company and start a new chapter advancing our
position as a global leader in precision care,” said Peter Arduini,
President and CEO of GE HealthCare. “We are on the verge of true
industry transformation as digital innovation reshapes the
experience of patients and providers with an increased need for
more precise, connected, and efficient care. GE HealthCare
colleagues worldwide are united in our purpose to create a world
where healthcare has no limits, and we look forward to delivering
for providers, patients, and shareholders in the years ahead.”
GE HealthCare launches with a presence in more than 160
countries and approximately 51,000 employees worldwide serving more
than one billion patients a year. The company invests more than $1
billion in R&D annually and generates approximately $18 billion
in revenue, with an installed base including more than 4 million
pieces of equipment across its four business segments – Imaging,
Ultrasound, Patient Care Solutions, and Pharmaceutical
Diagnostics.
The Company expects its addressable markets will expand from $84
billion in 2021 to $102 billion by 2025. That expansion provides
significant opportunities for growth and execution of the Company’s
precision care strategy to safely and securely integrate patient
data from imaging, lab, pathology, genomics, and other sources.
Precision care then layers those data with artificial intelligence,
using the Company’s Edison platform and digital apps. This
precision care strategy enables insights that help clinicians
diagnose diseases and determine the most appropriate treatment –
delivering the best possible outcome for the patient.
The spinoff of GE HealthCare was achieved by GE’s pro rata
distribution of approximately 80.1% of the outstanding shares of GE
HealthCare to GE shareholders. GE retained approximately 19.9% of
the outstanding shares of GE HealthCare common stock.
Both GE HealthCare’s President and CEO, Pete Arduini and CFO,
Helmut Zodl will be presenting at the 41st Annual J.P. Morgan
Healthcare Conference on January 10, 2023 at 11:15 am PT/2:15 pm
ET. Visit this website
(https://jpmorgan.metameetings.net/events/healthcare23/sessions/43746-ge-healthcare/webcast?gpu_only=true&kiosk=true)
to listen to their presentations and remarks. The company will also
issue its fourth quarter/full-year earnings on January 30, 2023 and
the earnings call can be heard at 8:00 am CT/ 9:00 am ET via this
link.
Forward-looking Statements
This release contains forward-looking statements. These
forward-looking statements might be identified by words, and
variations of words, such as “will,” “expect,” “may,” “would,”
“could,” “plan,” “believe,” “anticipate,” “intend,” “estimate,”
“potential,” “position,” “forecast,” “target,” “outlook,” and
similar expressions. These forward-looking statements may include,
but are not limited to, statements about the Company’s growth and
margin expansion; addressable markets; and strategy, innovation,
and investments. These forward-looking statements involve risks and
uncertainties, many of which are beyond the Company’s control.
Factors that could cause the Company’s actual results to differ
materially from those described in its forward-looking statements
include, but are not limited to, operating in highly competitive
markets; the actions or inactions of third parties with whom the
Company partners and the various collaboration, licensing, and
other partnerships and alliances the Company has with third
parties; demand for the Company’s products, services, or solutions
and factors that affect that demand; management of the Company’s
supply chain and the Company’s ability to cost-effectively secure
the materials it needs to operate its business; disruptions in the
Company’s operations; the global COVID-19 pandemic and its effects
on the Company’s business; maintenance and protection of the
Company’s intellectual property rights; the impact of potential
information technology, cybersecurity or data security breaches;
compliance with the various legal, regulatory, tax, and other laws
to which the Company is subject and related changes, claims, or
actions; environmental, social, and governance matters; the
Company’s ability to successfully complete strategic transactions;
the Company’s ability to operate effectively as an independent,
publicly-traded company and achieve the benefits the Company
expects from its spin-off from General Electric Company; and the
incurrence of substantial indebtedness in connection with the
spin-off and any related effect on the Company’s business. Please
also see the "Risk Factors" section of the Company’s Form 10 filed
with the U.S. Securities and Exchange Commission and any updates or
amendments it makes in future filings. There may be other factors
that could cause the Company’s actual results to differ materially
from those projected in any forward-looking statements the Company
makes. The Company does not undertake any obligation to update or
revise its forward-looking statements except as required by
applicable law or regulation.
About GE HealthCare
GE HealthCare is a leading global medical technology,
pharmaceutical diagnostics, and digital solutions innovator,
dedicated to providing integrated solutions, services, and data
analytics to make hospitals more efficient, clinicians more
effective, therapies more precise, and patients healthier and
happier. Serving patients and providers for more than 100 years, GE
HealthCare is advancing personalized, connected, and compassionate
care, while simplifying the patient’s journey across the care
pathway. Together our Imaging, Ultrasound, Patient Care Solutions,
and Pharmaceutical Diagnostics businesses help improve patient care
from prevention and screening, to diagnosis, treatment, therapy,
and monitoring. We are an $18 billion business with 51,000
employees working to create a world where healthcare has no
limits.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230104005222/en/
GE HealthCare Investor Contact Carolynne Borders
631.662.4317 carolynne.borders@gehealthcare.com
GE HealthCare Media Contact Jennifer Fox 414.530.3027
jennifer.r.fox@gehealthcare.com
General Electric (NYSE:GE)
Historical Stock Chart
From May 2023 to Jun 2023
General Electric (NYSE:GE)
Historical Stock Chart
From Jun 2022 to Jun 2023